Literature DB >> 28132526

Top-down approach to biological therapy of Crohn's disease.

Simon Hirschmann1, Markus F Neurath1.   

Abstract

INTRODUCTION: Crohn's disease (CD) is a chronic, immune-mediated condition with a potentially disabling and destructive course. Despite growing data on when to use a therapeutic 'top-down' strategy, clinical management of this complex disorder is still challenging. Currently, the discussion of 'top-down' strategy in CD mostly includes biological therapy alone or in combination. Areas covered: This article is based on a review of existing literature regarding the use of biological therapy in a 'top-down' approach for the treatment of Crohn's disease. The authors reviewed all the major databases including MEDLINE as well as DDW and ECCO abstracts, respectively. Expert opinion: A 'top-down' therapeutic approach in Crohn's disease is strongly supported by existing data in patients with several risk factors for a severe course of disease. Moreover, there is an increasing amount of published data recommending a more individualised therapeutic strategy to identify candidates for 'top-down' treatment, based on enhanced diagnostics using biomarkers. Emerging therapeutic approaches besides existing therapy concepts using biologicals may possibly redefine the 'top-down' therapeutic strategy for Crohn's disease in the future.

Entities:  

Keywords:  Crohn´s disease; IBD; colitis; individualized therapy; mucosal healing; prognosis

Mesh:

Year:  2017        PMID: 28132526     DOI: 10.1080/14712598.2017.1287170

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  5 in total

1.  Prognostic tools for identification of high risk in people with Crohn's disease: systematic review and cost-effectiveness study.

Authors:  Steven J Edwards; Samantha Barton; Mariana Bacelar; Charlotta Karner; Peter Cain; Victoria Wakefield; Gemma Marceniuk
Journal:  Health Technol Assess       Date:  2021-03       Impact factor: 4.014

2.  Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn's disease.

Authors:  Ryan C Ungaro; Saurabh Aggarwal; Ozlem Topaloglu; Wan-Ju Lee; Ryan Clark; Jean-Frederic Colombel
Journal:  Aliment Pharmacol Ther       Date:  2020-03-23       Impact factor: 8.171

Review 3.  Systematic Review with Network Meta-Analysis: Efficacy of Induction Therapy with a Second Biological Agent in Anti-TNF-Experienced Crohn's Disease Patients.

Authors:  Cristiano Pagnini; Spyros I Siakavellas; Giorgos Bamias
Journal:  Gastroenterol Res Pract       Date:  2018-07-17       Impact factor: 2.260

4.  The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.

Authors:  M Ellen Kuenzig; Eric I Benchimol; Lawrence Lee; Laura E Targownik; Harminder Singh; Gilaad G Kaplan; Charles N Bernstein; Alain Bitton; Geoffrey C Nguyen; Kate Lee; Jane Cooke-Lauder; Sanjay K Murthy
Journal:  J Can Assoc Gastroenterol       Date:  2018-11-02

5.  Cost-Effectiveness of Tight Control for Crohn's Disease With Adalimumab-Based Treatment: Economic Evaluation of the CALM Trial From a Canadian Perspective.

Authors:  Peter L Lakatos; Gilaad G Kaplan; Brian Bressler; Reena Khanna; Laura Targownik; Jennifer Jones; Yasmine Rahal; Kevin McHugh; Remo Panaccione
Journal:  J Can Assoc Gastroenterol       Date:  2022-03-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.